Hostname: page-component-74656f9884-rdgjk Total loading time: 0 Render date: 2026-11-06T22:57:47.500Z Has data issue: false hasContentIssue false

Vectorized Clay Nanoparticles in Therapy and Diagnosis

Published online by Cambridge University Press:  01 January 2024

Goeun Choi
Affiliation:
Center for Intelligent Nano-Bio Materials (CINBM), Department of Chemistry and Nanoscience, Ewha Womans University, Seoul 03760, Republic of Korea Institute of Tissue Regeneration Engineering (ITREN), Dankook University, Cheonan 31116, Republic of Korea
Huiyan Piao
Affiliation:
Center for Intelligent Nano-Bio Materials (CINBM), Department of Chemistry and Nanoscience, Ewha Womans University, Seoul 03760, Republic of Korea
Sairan Eom
Affiliation:
Center for Intelligent Nano-Bio Materials (CINBM), Department of Chemistry and Nanoscience, Ewha Womans University, Seoul 03760, Republic of Korea
Jin-Ho Choy*
Affiliation:
Center for Intelligent Nano-Bio Materials (CINBM), Department of Chemistry and Nanoscience, Ewha Womans University, Seoul 03760, Republic of Korea
Rights & Permissions [Opens in a new window]

Abstract

Over the past several decades, clay minerals have been applied in various bio-fields such as drug and drug additives, animal medicine and feed additives, cosmetics, biosensors, etc. Among various research areas, however, the medical application of clay minerals is an emerging field not only in academia but also in industry. In particular, cationic and anionic clays have long been considered as drug delivery vehicles for developing advanced drug delivery systems (DDSs), which is the most important of the various research fields including new drugs and medicines, in vitro and in vivo diagnostics, implants, biocompatible materials, etc., in nanomedicine. These applications are obviously related to global issues such as improvements in welfare and quality of life with life expectancy increasing. Many scientists, therefore, in various disciplines, such as clay mineralogy, material chemistry, molecular biology, pharmacology, and medical science, have been endeavoring to find solutions to such global issues. One of the strategic approaches is probably to explore new drugs possessing intrinsic therapeutic effects or to develop advanced materials with theranostic functions. With this is mind, discussions of examples of cationic and anionic clays with bio- and medical applications based on nanomedicine are relevant. In this tutorial review, nanomedicine based on clay minerals are described in terms of synthetic strategies of clay nanohybrids, in vitro and in vivo toxicity, biocompatibility, oral and injectable medications, diagnostics, theranosis, etc.

Information

Type
Research Article
Copyright
Copyright © Clay Minerals Society 2019
Figure 0

Table 1 Bio-applications of clay minerals

Figure 1

Fig. 1 Schematic crystal structures for a 2:1 type, and b 1:1 type clay minerals along the c axis

Figure 2

Fig. 2 Schematic crystal structures of a layered double hydroxide (LDH), b zinc basic salt (ZBS), and c hydrocalumite

Figure 3

Fig. 3 (a) Chemical structures and colors of MTT and its reduced formazan product, and (b) absorption spectra of MTT and MTT formazan (after Stockert et al. 2012, reproduced with permission from Elsevier)

Figure 4

Table 2 In vitro and in vivo toxicities of clay minerals and their clay hybrids

Figure 5

Fig. 4 (a) and (b) accumulation of LDH nanoparticles in organs of tumor-bearing mice treated with PBS (control), LDH, MTX, or MTX-LDH for 5 weeks (n = 3 for each group). On the first day after the final treatment, the mice were sacrificed and organs, blood, and tumors were collected for measurement of Mg and Al contents, the major components of LDH (after Choi et al. 2014, reproduced with the permission of Nature Research)

Figure 6

Fig. 5 Innate immune responses and liver toxicity of the LDH-FA/siSurvivin treatment (n = 4 per group). (a) Inflammatory cytokine level (IL-6 level) analyzed at 6 h after LDH-FA/siSurvivin treatment, (b) ALT and AST levels, and (c) H&E staining of liver tissues performed on day 3 after treatment (original magnification: × 100) (after Park et al., 2016, reproduced with the permission of Wiley)

Figure 7

Fig. 6 Chemical modifications of clay hybrid materials. Schematic procedures for (a) polymer coating on clay-drug nanohybrid, (b) self-assembling of Laponite®-drug hybrid with polymer (after Wang et al., 2018), (c) immobilizing drug molecules in aminoclay nanohybrid, and (d) bifunctionalizing internal and external surfaces of halloysite nanotubes (after Yah et al., 2012, reproduced with the permission of the American Chemical Society)

Figure 8

Fig. 7 Reaction routes for clay hybrid materials; (a) co-precipitation, (b) ion-exchange, (c) exfoliation-reassembling, and (d) calcination-reconstruction

Figure 9

Table 3 Summary of oral medicine using clay minerals

Figure 10

Fig. 8 (A) Release profiles of APZ (a) in deionized water with 1% Tween 80, and (b) in simulated gastric fluid (pH 1.2) with 1% Tween 80 (modified from Oh et al., 2013). (B) Pharmacokinetic curves of AS after oral administration (a), and scanning electron microscopy (SEM) images of Eudragit® L100-coated AS-ZBS (b) (after Kim et al., 2016, reproduced with the permission of Wiley)

Figure 11

Table 4 Summary of injectable medicine using clay minerals

Figure 12

Fig. 9 A Biodistribution studies of boron in each tissue of U87 xenograft tumor-bearing mice treated with (a) BSH and (b) BSH-LDH for 2 h after administration (after Choi et al., 2017). B Antitumor effects of DOX@HNTs-PEG-FA in four T1-bearing mice; (a) tumor growth curves of mice treated with saline, HNTs, HNTs-PEG-FA, DOX, and DOX@HNTs-PEG-FA (5 mg DOX equiv./kg) via intravenous injection, and (b) photographs of excised 4 T1 solid tumor from different groups on the 22nd day. The values are represented as mean ± SD (n = 6). *P < 0.05, **P < 0.01, vs. control; #P < 0.05 vs. DOX (after Wen et al. 2015, reproduced with the permission of the Royal Society of Chemistry)

Figure 13

Table 5 Clay minerals as carriers of molecular imaging agents for nanomedicine

Figure 14

Fig. 10 A Positron emission from radioisotope. B (a) Positron emission tomography (PET) scanner and (b) cross-sectional PET image after injection with 2-[18F]fluoro-2-deoxy-D-glucose (FDG) (after Gambhir (2002, reproduced with the permission of Nature Reviews))

Figure 15

Table 6 Important parameters for different imaging technologies (after Dufort et al. 2010, reproduced with the permission of Elsevier; Data from Korea Institute of Radiological & Medical Sciences)

Figure 16

Fig. 11 In vivo T2-weighted MR images of tumor (red circle), liver (red arrow), and kidney (red star) after intravenous injection of Laponite®-Fe3O4 nanoparticles for 0 h, 2 h, 4 h, and 6 h (after Ding et al. 2016, reproduced with the permission of the Royal Society of Chemistry)

Figure 17

Fig. 12 (A) Different transdermal pathways of clay nanoparticles. (B) (a) In vitro drug release, and (b) permeation behaviors of the chitosan/montmorillonite K transdermal films (after Thakur et al., 2016, reproduced with the permission of Wolters Kluwer Medknow Publications)